Semaglutide is ordered as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), having a place with a class of meds pointed toward copying the activities of the regular chemical GLP-1
While semaglutide was initially approved primarily for diabetes management, it has increasingly been prescribed off-label by weight-loss specialists due to its remarkable results in clinical trials
Metabolic dysfunctionassociated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis, NASH) is a major research focus, characterized by excessive hepatic fat accumulation, inflammation, and hepatocellular injury
A 2024 phase 2 RCT (Hansen et al., eClinicalMedicine) found a 2.6% reduction in hip bone mineral density within 52 weeks in a specific study population using semaglutide at 1.0 mg weekly
If you want more related reading, browse all of our GLP-1 guides, dive into semaglutide guides, compare ideas in our tirzepatide guides, review our Mounjaro guides and Zepbound guides, and explore the full Jabby blog plus our medication comparisons for more tracking tips
Lets take a look at some statistics
